ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma.

ABSTRACT:

Background

Lung adenocarcinoma (LUAD) is a common subtype of non-small cell lung cancer with high morbidity and mortality rates and is usually detected at advanced stages because of the early onset of metastasis. Adenosine deaminase RNA-specific 1 (ADAR1) is an RNA editing enzyme that catalyzes the important physiological process of adenosine-to-inosine editing and has been shown to participate in the progression of LUAD. Increasing evidence has suggested that immune infiltration of the tumor immune microenvironment has prognostic value for most human solid organ malignancies; however, much is unknown about the functions of ADAR1.

Methods

The expression of ADAR1 was analyzed in The Cancer Genome Atlas -LUAD database and validated in our LUAD cohort. To assess the prognostic

SUBMITTER: Yang W 

PROVIDER: S-EPMC10358204 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature